Recomendaciones para el diagnóstico, clasificación y el manejo de la urticaria

Autores/as

  • Giovanni Sedó Mejía Caja Costarricense del Seguro Social, Hospital San Juan de Dios
  • Adrián Yong Rodríguez Caja Costarricense del Seguro Social, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera"
  • Osvaldo Monge Masís Caja Costarricense del Seguro Social, Hospital San Juan de Dios
  • Benjamín Hidalgo Matlock Caja Costarricense del Seguro Social, Hospital México

DOI:

https://doi.org/10.51481/amc.v57i3.886

Palabras clave:

urticaria aguda, urticaria crónica, urticaria espontánea, omalizumab, ciclosporina, antihistamínicos

Resumen

La urticaria es la aparición súbita de habones en la piel con o sin angioedema, es una enfermedad con un curso benigno, pero con un impacto negativo en la calidad de vida de quien la padece; se trata de una entidad relativamente común, desencadenada por varios gatillos, muchas veces reconocibles con una buena historia clínica, sin embargo, en la mayoría de los casos estos son desconocidos, como en la urticaria crónica. Su fisiopatología está mediada por una respuesta inmune y su tratamiento es sintomático con antihistamínicos, aunque en ocasiones se debe recurrir a inmunomoduladores.

Citas

Saini S, Rosen K, Hsieh H, Wong D, Conner E, Kapplan A et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy ClinImmunol. 2011;128:567-73 e1.

O’Donnell B. Urticaria: impact on quality of life and economic cost. Immunol Allergy Clin North Am. 2014;34:89-104.

Bernstein J, Lang D, Khan D. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy ClinImmunol. 2014;133:1270-7.

Sabroe A. Acute Urticaria. Immunol Allergy Clin North Am. 2014;34:11-21.

Bruske I, Satndl M, Weidinger S, Klümper C, Hoffmann B, Schaaf B et al. Epidemiology of urticaria in infants and young children in Germany results from the German LISAplus and GINIplus Birth Cohort Studies. Pediatr Allergy Immunol. 2014;25:36-42.

Zuberbier T, Aberer W, Asero R, Canonica W, Church M, Gimenez A, et al. The EAACI/GALEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014;69:868-87.

Zuberbier T, Asero R, Bindslev C, Canonica W, Church M, Giménez A, et al. EAACI/GALEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria, Allergy. 2009;64:1417-26.

Armengot M, Velasco M, Nicolas B, Pont V, Quecedo E, Gimeno E. Omalizumab in chronic urticaria: a retrospective series of 15 cases. Dermatol Ther. 2013;26:257-9.

Maurer M, Rosen K, Hsieh H, Sarbjit S, Grattan C, Gimenéz A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924-35.9.

Metz M, Ohanyan T, Church M, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73:57-62.

Saini S. Chronic spontaneous urticaria etiology and pathogenesis. Immunol Allergy Clin North Am. 2014;34:33-52.

Maurer M, Rosen K, Hsieh H. Omalizumab for chronic urticaria. N Engl J Med. 2013;368:2530.

Le Fourn E, Giraudeau B, Chosidow O, Doutre MS, Lorette G. Study design and quality of reporting of randomized controlled trials of chronic idiopathic or autoimmune urticaria: review. PloS One. 2013;8:e70717.

Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12:406-11.

Sánchez M, Asero R, Ansotegui I, Baiarini I, Bernstein J, Canonica W, et al. Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide Perspective, WAO Journal. 2012;11:25-147.

Curto L, Silvestre J, Giménez A. Actualización en el tratamiento de la urticaria crónica. Actas Dermosifiliogr 2013;826:1-14.

Frances L, Leiva M, Silvestre J. Omalizumab in the treatment of chronic urticaria. Actas Dermosifiliogr. 2014;105:45-52.

Viswanathan R, Moss M, Mathur S. Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria. Allergy AsthmaProc. 2013;34:44652.

Plaza A, Giner M, Piquer M. Urticaria. En: Méndez J. Huerta J, Bellanti J, Ovilla R, Escobar A. Alergia: enfermedad multisistémica Fundamentos básicos y clínicos. México. Editorial Médica Panamericana; 2008:243-50.

Abajian M, Schoepke N, Altrichter S, Zuberbier M, Maurer M. Physical urticarias and cholinergic urticarias, Immunol Allergy Clin North Am 2014;34:77-88.

Hide M, Hiragun M, Hiragun T, Diagnostic test for urticaria, Immunol Allergy Clin North Am 2014;34:53-72.

Caffarelli C, Cuomo B, Cardinale F. Aetiological factors associated with chronic urticaria in children: a systematic review. Acta Derm Venereol 2013;93:26872.

Metz M, Krull C, Maurer M. Histamine, TNF, C5a, IL-6, -9, -18, -31, -33, TSLP, neopterin, and VEGF are not elevated in chronic spontaneous urticaria. J Dermatol Sci 2013;70:222-5.

Tedeschi A, Kolkhir P, Asero R, Pogorelov D, Olisova O, Kochergin N, et al. Chronic urticaria and coagulation: pathophysiological and clinical aspects, Allergy 2014;69:683-691.

Bossi F, Peerschker E, Ghebrehiwet B. Cross-talk between the complement and the kinin system in vascular permeability, Immunology Letter 2011; 30:7-13

Posthumus J, Tinana A, Mozena J, Steinke J, Borish L. Autoimmune mechanisms in chronic idiopathic urticaria. J Allergy Clin Immunol 2012; 130:814-6.

Maurer M. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol 2013; 93:168-74.

Konstantinou G, Asero R, Ferrer M, Knol E, Maurer M, Raap U et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy 2013; 68:27-36.

Altman K, Chang C. Pathogenic Intracellular and Autoimmune Mechanisms in Urticaria and Angioedema, Clin Rev Allergy Immunol 2013;45:47-62.

Jariwala S, Moday H, Lourdes de Asis M, Fodeman J, Hudes G, de Vos G, et al. The Urticaria Severity Score: a sensitive questionnaire/index for monitoring response to therapy in patients with chronic urticaria, J Allergy Clin Immunol 2009; 102: 475-82.

Weller K, Groffik A, Church M, Hawro T, Krause K, Metz M, Martus P, et al. Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control, J Allergy Clin Immunol 2014;133(5):1365-72.

Machura E, Jónska-Golus M, Krakowczyk H, Kaspersk A, Ziora K. Etiology and clinical course of urticaria in hospitalized children. Med Wieku Rozwoj. 2013; 23:64-71.

Tardox J, Gutta R, Radojicic C, Lang D. Utility of routine laboratory testing in the management of chronic urticaria/angioedema, Ann Allergy Clin Immunol 2011; 107:239-243.

Maurer M, Magerl M, Metz M, Zuberbier T. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges 2013; 11:971–978.

Ting T. Diagnosis and management of cutaneous vasculitis in children, Pediatr Clin North Am 2013;61:321-346.

Akin C, Peter V, Dean D, Metcalfe D. Mast cell activation syndrome: Propose diagnostic criteria, J Allergy Clin Immunol 2010;126: 1099-1104.

Kanazawa N. Hereditary Disorders Presenting with Urticaria, Immunol Allergy Clin North Am 2014;34:169-179.

Viegas L, Ferreira M, Kaplan A. The maddening itch: an approach to chronic urticaria. J Investig Allergol ClinImmunol 2014; 24:1-5.

Sánchez M, Caballero F, Capriles H. Treatment of recalcitrant chronic urticaria with nonsedating Antihistamines: Is there evidence for updosing? J Investig Allergol Clin Immunol 2013; 23: 141-44.

Staevska M, Popov T, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy ClinImmunol 2010; 125:676-82.

Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy ClinImmunol 2009; 123:672-9.

Krause K, Spohr A, Zuberbier T, Church M, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68:921-8.

Konstantinou G, Asero R, Maurer M, Sabroe R, Schmid P, Grattan C. EAACI/ GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy 2009; 64:1256-68.

Ferrer M, Sastre J, Jáuregui I, Davila I, Montoro J, del Cuvillo A, et al. Effect of antihistamine up-dosing in chronic urticaria, J Investig Allergol ClinImmunol 2011;21(3):34-9

Church M, Maurer M. H1-antihistamines and urticaria: how can we predict the best drug for our patient? Clin Exp Allergy 2012;42:1423-29.

Krause K, Spohr A, Zuberbier T, Church M, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria, Allergy 2013;68:921-28.

Simons E, Simons K. Histamine and H1-antihistamines: Celebrating a century of progress. J Allergy Clin Immunol 2011; 128(6):1139-50.

Maurer M, Magerl M, Metz M, Zuberbier T. Diagnosis and therapy of chronic urticaria-what is expected from the revision and update of the international guidelines? A report of the public consensus conference “URTICARIA 2012”, Hautarzt 2013;64:638-43.

Fernando S, Broadfoot A. Chronic urticaria--assessment and treatment. Aust Fam Physician 2010;39:135-8.

Kropfl L, Maurer M, Zuberbier T. Treatment strategies in urticaria. Expert Opin Pharmacother 2010; 11:1445-50.

Saini S, Bindslev C, Maurer M, ,Grob J, Bülbül E, Bradley M, et al. Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H-Antihistamines: A Randomized, Placebo-Controlled Study. J Invest Dermatol 2014;00:1-9.

Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali J, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy ClinImmunol 2013;132:101-9.

Lemoli E, Piconi S, Fusi A, Borgonovo L, Borelli M, Trabattoni D. Immunological effects of omalizumab in chronic urticaria: a case report. J Investig Allergol Clin Immunol 2010;20:252-4.

Makris M, Maurer M, Zuberbier T. Pharmacotherapy of chronic spontaneous urticaria. Expert OpinPharmacother 2013;14:2511-9.

Nettis E, Colanardi M, Soccio A, Ferrannini A, Vacca A. Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2006;155:1279-82.

Boubouka C, Charissi C, Kouimintzis D, Kalogeromitros D, Stavropoulos P, Katsarou A. Treatment of autoimmune urticaria with low-dose cyclosporin A: A one-year follow-up. Acta DermVenereol 2011;91:50-4.

Trojan T, Khan D. Calcineurin inhibitors in chronic urticaria. Curr Opin Allergy Clin Immunol 2012;12:412-20.

Doshi D, Weinberger M. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol 2009;26:409-13.

Dreyfus DH. Observations on the mechanism of omalizumab as a steroidsparing agent in autoimmune or chronic idiopathic urticaria and angioedema. Ann Allergy Asthma Immunol 2008;100:624-5.

Bergstrom K. Chronic urticaria: Omalizumab and review of therapeutic options. J DrugsDermatol 2013;12:715-6.

Labrador M, Valero A, Velasco M, Jáuregui I, Sastre J, Bartra J, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther 2013;13:1225-8.

Sussman G, Hebert J, Barron C, Bian J, Caron R, Laflamme S, et al. Reallife experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol 2014;112:170-4.

Descargas

Publicado

2015-07-02

Cómo citar

Mejía, G. S., Rodríguez, A. Y., Masís, O. M., & Matlock, B. H. (2015). Recomendaciones para el diagnóstico, clasificación y el manejo de la urticaria. Acta Médica Costarricense , 57(3), 102-112. https://doi.org/10.51481/amc.v57i3.886